COMMON STOCK PURCHASE WARRANT TAYSHA GENE THERAPIES, INC.Common Stock Purchase Warrant • April 5th, 2023 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until 5:00 p.m. (New York City time) on [•], 2033 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), up to [•] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock, on the terms set forth herein. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 3(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 5th, 2023 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 5, 2023, by and between Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), with its principal place of business at 3000 Pegasus Park Drive, Ste 1430, Dallas, Texas, 75247 and the purchasers named in Schedule 1 hereto (the “Purchaser”) with its principal place of business at 9 Campus Drive, Suite 103, Parsippany, NJ 07054. Capitalized terms used herein but not otherwise defined shall have the meanings given to them in Section 1.5.
